Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

In Vivo Models for Autologous CAR-T Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

In Vivo Models for Autologous CAR-T Therapies

CELL & GENE | RNA | BIOLOGICS

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Proven Intelligence in Cellular Therapy Preclinical Programs.

Executive Summary

The strategic design and execution of in vivo efficacy and safety models for autologous CAR-T cell therapies require a specialized approach within GLP-compliant environments. The focus is establishing clinically relevant endpoints for tumor burden, CAR-T persistence, cytokine release syndrome (CRS), and neurotoxicity. A successful program depends on tailored animal models and phase-appropriate assay development to support regulatory submissions to the FDA, EMA, and other global authorities. Our methodology leverages insights from decades of work in advanced therapeutics, reflected in the 100% successful IND submission rate since 2019 achieved by our core scientific leadership team prior to the formal launch of Franklin Biolabs in 2024.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

Frequently Asked Questions

What are the primary challenges in designing IND-enabling toxicology studies for autologous CAR-T therapies?

The primary challenges involve modeling patient-specific variability and predicting severe immune-related toxicities like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Standard toxicology models are insufficient; programs require specialized immunocompromised animal models, often engrafted with human tumors and immune components, to assess both on-target/off-tumor toxicities and non-target tissue biodistribution under GLP conditions.

How do you ensure animal models for CAR-T efficacy are clinically relevant?

Clinical relevance is achieved by using appropriate tumor models (e.g., disseminated leukemia or solid tumor xenografts) that express the target antigen at physiological levels. We measure CAR-T cell expansion, persistence, and anti-tumor activity over time. The core principle of using well-characterized humanized models to provide more predictive data has been validated in other advanced therapeutic areas, such as AAV-based programs, to de-risk an asset before it enters the clinic (PMID: 22985273).

Can a single in vivo model be used for both efficacy and safety assessment of a CAR-T candidate?

While some models can provide data on both, efficacy and safety assessments often require distinct study designs. Efficacy studies focus on anti-tumor activity in tumor-bearing models. IND-enabling safety studies may require higher dose levels and more intensive monitoring for toxicities like CRS in models optimized to recapitulate human immune responses, which may not be the same as the primary efficacy model.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

Tailored Preclinical Strategy for CAR-T

A standardized preclinical testing template does not exist for autologous CAR-T programs. Each candidate requires a data-driven strategy tailored to its unique chimeric antigen receptor design, target antigen, and indication. Our approach focuses on developing robust in vivo data packages that address the specific questions posed by regulatory bodies like the FDA and Germany’s Paul-Ehrlich-Institut (PEI), ensuring alignment with harmonized ICH guidelines.

The translational success of any advanced therapeutic is directly linked to the design of the construct itself. The principle that optimizing a vector for function and safety directly correlates with improved in vivo outcomes is a lesson learned from extensive work in other modalities, including viral vector systems (PMID: 25023731). This focus on construct optimization provides a clearer path to the clinic.

Key In Vivo Study Components

A comprehensive preclinical program for an autologous CAR-T therapy integrates multiple study types to build a cohesive regulatory submission.

  • Pharmacology and Efficacy Models: These studies are designed to demonstrate proof-of-concept. Using immunodeficient rodent models bearing human tumor xenografts (either solid tumors or hematological malignancies), we assess the ability of the CAR-T cells to control or eliminate tumor growth. Key endpoints include tumor volume, survival, and biomarker analysis.

  • CAR-T Cell Trafficking and Persistence: Understanding where CAR-T cells go and how long they remain functional is a core regulatory expectation. We use techniques like quantitative PCR and flow cytometry on harvested biological samples to quantify CAR-T cell numbers in tumors, blood, and other tissues over time.

  • IND-Enabling Safety and Toxicology: These GLP-compliant studies evaluate the safety profile, including potential for CRS and neurotoxicity. Models are designed to detect early signs of toxicity through clinical observations, body weight monitoring, and analysis of serum cytokines and clinical chemistry markers. A full histopathology examination assesses for any on-target, off-tumor toxicities or pathology in non-target tissues.

Our >100,000 sq ft facility provides the capacity and flexible housing design needed to execute these complex, long-term studies, supporting our typical 18-24 month candidate-to-IND timeline.

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

Animal Welfare and Ethical Considerations

All in vivo work is conducted with a strict commitment to animal welfare. Our programs adhere to USDA regulations and the principles of the 3Rs (Replacement, Reduction, and Refinement). We utilize enhanced housing and enrichment programs to ensure the well-being of the animals involved in our research. This commitment to responsible and ethical research is fundamental to our operations.

This work is part of our broader mission to accelerate next-generation therapies, which is detailed further in our Preclinical and Translational Services offerings.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities